Atai Beckley (ATAI) Stock Price, News & Analysis

Company Overview

AtaiBeckley AG (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic and other novel therapeutics for mental health conditions. The company was formed through the combination of atai Life Sciences and Beckley Psytech and focuses on treatments intended to address conditions such as depression, anxiety, post-traumatic stress disorder and substance-use disorders.

Its development programs include VLS-01, an investigational formulation of N,N-dimethyltryptamine (DMT), and BPL-003, an intranasal formulation of 5-MeO-DMT being studied for conditions including alcohol use disorder and depression. AtaiBeckley also evaluates non-psychedelic compounds and digital or technology-enabled treatment approaches intended to support the development and delivery of mental health therapies. Its products remain investigational and are not broadly approved for commercial use.

The company operates internationally, with activities and research programs spanning the United States and Europe. AtaiBeckley is led by co-founder and Chief Executive Officer Florian Brand. Beckley Psytech was founded by Amanda Feilding, whose work in psychedelic research and drug development contributed to the company’s combined platform.

Key Stats

• Today's Range: $7.35 to $7.35
• 50-Day Range: $7.14 to $7.44
• 52-Week Range: $3.27 to $7.45
• Volume: N/A
• Average Volume: 13.29 million shs
• Market Capitalization: $2.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.56
• Consensus Rating: Hold

Atai Beckley Stock Analysis - MarketRank™

Atai Beckley scored higher than 36% of companies evaluated by MarketBeat, and ranked 700th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Atai Beckley has received a consensus rating of Hold. The company's average rating score is 2.06, and is based on 1 strong buy rating, no buy ratings, 14 hold ratings, and 1 sell rating.

Upside Potential

Atai Beckley has a consensus price target of $10.56, representing about 43.6% upside from its current price of $7.35.

Amount of Analyst Coverage

Atai Beckley has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atai Beckley are expected to grow in the coming year, from ($0.39) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atai Beckley is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atai Beckley is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atai Beckley has a P/B Ratio of 10.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATAI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atai Beckley does not currently pay a dividend.

Dividend Growth

Atai Beckley does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Atai Beckley this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Atai Beckley to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atai Beckley insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Atai Beckley is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

28.41% of the stock of Atai Beckley is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/22/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ATAI
• CIK: 1420529
• Web: www.ataibeckley.com
• Phone: 31 20 793 2536
• Fax: N/A
• Employees: 80
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Atai Beckley: $10.56
• High Price Target: $16.00
• Low Price Target: $7.45
• Potential Upside/Downside: +43.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.06
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$660.05 million
• Net Margins: -14,938.36%
• Pretax Margin: N/A
• Return on Equity: -88.30%
• Return on Assets: -58.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.09 million
• Price / Sales: 666.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 10.65

Miscellaneous

• Outstanding Shares: 370,860,000
• Free Float: 297,434,000
• Market Cap: $2.73 billion
• Optionable: Optionable
• Beta: 1.54